NO20051714L - Long-acting Erythropoietins That Maintain Tissue Protective Activity to Endogenous Erythropoietin - Google Patents
Long-acting Erythropoietins That Maintain Tissue Protective Activity to Endogenous ErythropoietinInfo
- Publication number
- NO20051714L NO20051714L NO20051714A NO20051714A NO20051714L NO 20051714 L NO20051714 L NO 20051714L NO 20051714 A NO20051714 A NO 20051714A NO 20051714 A NO20051714 A NO 20051714A NO 20051714 L NO20051714 L NO 20051714L
- Authority
- NO
- Norway
- Prior art keywords
- long
- acting
- erythropoietins
- tissue protective
- protective activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Analytical Chemistry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
2005- -06- 0 6 Sammendrag O. nr. E39946 Fremgangsmåter for å øke hematokritt hos et individ mens de opprettholder de vevsbeskyttende endogene aktivitetene gjennom administrasjon av en farmasøytisk forbindelse som inneholder kjemisk modifisert langtidsvirkende erytropoietin. Også angitt er de nye kjemisk modifiserte langtidsvirkende erytropoietinene, fremgangsmåter for produksjon av de kjemisk modifiserte, langtidsvirkende erytropoietiner, og sammensetninger som omfatter de kjemisk modifiserte langtidsvirkende erytropoietinene.2005/06/06 Summary O. No. E39946 Methods for increasing hematocrit in an individual while maintaining the tissue-protective endogenous activities through administration of a pharmaceutical compound containing chemically modified long-acting erythropoietin. Also disclosed are the novel chemically modified long-acting erythropoietins, methods for producing the chemically modified, long-acting erythropoietins, and compositions comprising the chemically modified long-acting erythropoietins.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40902002P | 2002-09-09 | 2002-09-09 | |
PCT/US2003/028073 WO2004022577A2 (en) | 2002-09-09 | 2003-09-09 | Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20051714L true NO20051714L (en) | 2005-06-06 |
Family
ID=31978712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20051714A NO20051714L (en) | 2002-09-09 | 2005-04-06 | Long-acting Erythropoietins That Maintain Tissue Protective Activity to Endogenous Erythropoietin |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1545586A4 (en) |
JP (1) | JP2006511468A (en) |
KR (1) | KR20050083682A (en) |
CN (2) | CN101371920A (en) |
AU (1) | AU2003273297A1 (en) |
BR (1) | BR0314152A (en) |
CA (1) | CA2497960A1 (en) |
EA (1) | EA007812B1 (en) |
IL (1) | IL174178A0 (en) |
IS (1) | IS7731A (en) |
MX (1) | MXPA05002617A (en) |
NO (1) | NO20051714L (en) |
PL (1) | PL375741A1 (en) |
WO (1) | WO2004022577A2 (en) |
ZA (1) | ZA200505423B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7718363B2 (en) | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
WO2006061853A2 (en) * | 2004-12-10 | 2006-06-15 | Serum Institute Of India Limited | Novel erythropoietic compounds and a process for producing erythropoietic compounds |
TWI376234B (en) | 2005-02-01 | 2012-11-11 | Msd Oss Bv | Conjugates of a polypeptide and an oligosaccharide |
KR20170027868A (en) | 2005-08-05 | 2017-03-10 | 아라임 파마슈티칼즈, 인크. | Tissue protective peptides and uses thereof |
SG188161A1 (en) | 2008-01-22 | 2013-03-28 | Araim Pharmaceuticals Inc | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
CN101671388B (en) * | 2008-09-09 | 2013-01-02 | 曹国栋 | Blood brain barrier penetrable erythropoietin (EPO) and application thereof |
RU2475273C1 (en) * | 2012-04-02 | 2013-02-20 | Юлия Николаевна Козлова | Method of obtaining polymeric cement of medical purpose |
CN102746405B (en) * | 2012-07-24 | 2013-08-21 | 深圳赛保尔生物药业有限公司 | Continuous pegylation reaction method for recombinant human erythropoietin (EPO) |
RU2664588C2 (en) * | 2015-11-05 | 2018-08-21 | Закрытое Акционерное Общество "Биокад" | Extended factor of human erythropoiesis and a therapeutic agent based thereon |
CN109310741A (en) | 2016-04-29 | 2019-02-05 | 阿拉伊姆药品公司 | For preventing and treating organization protection's peptide of disease relevant to tissue damage and obstacle |
CN112741895A (en) * | 2021-01-19 | 2021-05-04 | 中国人民解放军陆军军医大学 | Application of EPO analog in preparing medicament for treating sepsis |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20010288A1 (en) * | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | ERYTHROPOYETIN DERIVATIVES |
JP5022551B2 (en) * | 2000-04-21 | 2012-09-12 | アムジエン・インコーポレーテツド | Methods and compositions for the prevention and treatment of anemia |
EP1525889A1 (en) * | 2000-05-15 | 2005-04-27 | F. Hoffmann-La Roche Ag | Liquid pharmaceutical composition containing an erythropoietin derivative |
-
2003
- 2003-09-09 ZA ZA200505423A patent/ZA200505423B/en unknown
- 2003-09-09 MX MXPA05002617A patent/MXPA05002617A/en unknown
- 2003-09-09 AU AU2003273297A patent/AU2003273297A1/en not_active Abandoned
- 2003-09-09 KR KR1020057004045A patent/KR20050083682A/en not_active Application Discontinuation
- 2003-09-09 EA EA200500473A patent/EA007812B1/en not_active IP Right Cessation
- 2003-09-09 CN CNA2008101490873A patent/CN101371920A/en active Pending
- 2003-09-09 EP EP03755796A patent/EP1545586A4/en not_active Withdrawn
- 2003-09-09 CA CA002497960A patent/CA2497960A1/en not_active Withdrawn
- 2003-09-09 BR BR0314152-7A patent/BR0314152A/en not_active IP Right Cessation
- 2003-09-09 CN CNA038249154A patent/CN1729015A/en active Pending
- 2003-09-09 WO PCT/US2003/028073 patent/WO2004022577A2/en active Application Filing
- 2003-09-09 JP JP2004534745A patent/JP2006511468A/en not_active Withdrawn
- 2003-09-09 PL PL03375741A patent/PL375741A1/en not_active Application Discontinuation
-
2005
- 2005-03-08 IS IS7731A patent/IS7731A/en unknown
- 2005-04-06 NO NO20051714A patent/NO20051714L/en not_active Application Discontinuation
-
2006
- 2006-03-08 IL IL174178A patent/IL174178A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
IS7731A (en) | 2005-03-08 |
CN101371920A (en) | 2009-02-25 |
BR0314152A (en) | 2005-07-12 |
EA007812B1 (en) | 2007-02-27 |
ZA200505423B (en) | 2008-08-27 |
EA200500473A1 (en) | 2005-10-27 |
EP1545586A2 (en) | 2005-06-29 |
WO2004022577A3 (en) | 2004-09-16 |
PL375741A1 (en) | 2005-12-12 |
WO2004022577A2 (en) | 2004-03-18 |
JP2006511468A (en) | 2006-04-06 |
AU2003273297A8 (en) | 2004-03-29 |
KR20050083682A (en) | 2005-08-26 |
AU2003273297A1 (en) | 2004-03-29 |
EP1545586A4 (en) | 2007-09-26 |
IL174178A0 (en) | 2006-08-01 |
CA2497960A1 (en) | 2004-03-18 |
CN1729015A (en) | 2006-02-01 |
MXPA05002617A (en) | 2005-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20051714L (en) | Long-acting Erythropoietins That Maintain Tissue Protective Activity to Endogenous Erythropoietin | |
AU6434600A (en) | Biphenyl derivatives, production thereof and use as medicines | |
DE60236541D1 (en) | INHIBITORS OF 11-BETA-HYDROXYSTEROIDDEHYDROGENASE TYPE 1 | |
NO20042161L (en) | Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 | |
SE0001899D0 (en) | New compounds | |
NO20080164L (en) | N- (pyridin-2-yl) -sulfonamidderivater | |
RS20090086A (en) | Nucleoside analogs with carobxamidine modified monocyclic base | |
CL2010000606A1 (en) | Use of erythropoietin derivatives in the preparation of a useful medicine to protect, maintain, improve or recover the viability of cells that respond to erythropoietin under abnormal conditions that affect the associated cells, tissues or organs; Erythropoietin derivatives and composition comprising them (divisional of application 3188-2001). | |
SE8804629D0 (en) | NEW THERAPEUTICALLY ACTIVE COMPOUNDS | |
DE69922676D1 (en) | N-ARALKYLAMINOTETRALINES AS NEUROPEPTIDE Y-Y5 RECEPTOR LIGANDS | |
DK1178958T3 (en) | N-cyanomethylamides as protease inhibitors | |
MY119231A (en) | Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them | |
MXPA01006917A (en) | Topical composition comprising n-acetylaldosamines or n-acetylamino acids. | |
SE9504661D0 (en) | New compounds | |
IT1312377B1 (en) | COMPOSITIONS BASED ON TIOTIC ACID, CISTEIN AND / OR N-ACETYL CISTEINADA USE IN PHARMACEUTICAL, DIETETIC AND COSMETIC PREPARATIONS | |
DK1047397T3 (en) | Topical preparations for increasing glutathione production | |
NO883229D0 (en) | NEW BENZIMIDAZOLD DERIVATIVES, PROCEDURES FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATION CONTAINING SUCH DERIVATIVES. | |
TR200000737T2 (en) | Substituted chroma derivatives. | |
DK0825197T3 (en) | New 6-hydroxy and 6-oxo-androstan derivatives active in relation to the cardiovascular system and pharmaceutical preparations | |
DK0823903T3 (en) | Heterocyclic biaryl compounds, pharmaceutical preparations and cosmetic compositions containing them, and uses | |
EA200400708A1 (en) | INHIBITORS 11-BETA-HYDROXYSTEROID DEGYDROGENASE TYPE 1 | |
ATE349221T1 (en) | EXTRACT WITH ANTI-TUMORAL AND ANTI-TOXIC EFFECT | |
DE60309480D1 (en) | VITAMIN D ANALOG | |
RS44304A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
IT1306147B1 (en) | DERIVATIVES OF ACTIVE INGREDIENTS FOR THERAPEUTIC AND / OR NUTRITIONAL ACTIVITIES AND COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION CONTAINING SUCH |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |